Novel Inhibitors of the MDM2-p53 Interaction Featuring Hydrogen Bond Acceptors as Carboxylic Acid Isosteres

详细信息    查看全文

• 作者：Ana Z. Gonzalez ; Zhihong Li ; Hilary P. Beck ; Jude Canon ; Ada Chen ; David Chow ; Jason Duquette ; John Eksterowicz ; Brian M. Fox ; Jiasheng Fu ; Xin Huang ; Jonathan Houze ; Lixia Jin ; Yihong Li ; Yun Ling ; Mei-Chu Lo ; Alexander M. Long ; Lawrence R. McGee ; Joel McIntosh ; Jonathan D. Oliner ; Tao Osgood ; Yosup Rew ; Anne Y. Saiki ; Paul Shaffer ; Sarah Wortman ; Peter Yakowec ; Xuelei Yan ; Qiuping Ye ; Dongyin Yu ; Xiaoning Zhao ; Jing Zhou ; Steven H. Olson ; Daqing Sun ; Julio C. Medina
• 刊名：Journal of Medicinal Chemistry
• 出版年：2014
• 出版时间：April 10, 2014
• 年：2014
• 卷：57
• 期：7
• 页码：2963-2988
• 全文大小：1111K
• 年卷期：v.57,no.7(April 10, 2014)
• ISSN：1520-4804

文摘

We previously reported the discovery of potent and selective morpholinone and piperidinone inhibitors of the MDM2-p53 interaction. These inhibitors have in common a carboxylic acid moiety that engages in an electrostatic interaction with MDM2-His96. Our continued search for potent and diverse inhibitors led to the discovery of novel replacements for these acids uncovering new interactions with the MDM2 protein. In particular, using pyridine or thiazole as isosteres of the carboxylic acid moiety resulted in very potent analogues. From these, AM-6761 (4) emerged as a potent inhibitor with remarkable biochemical (HTRF IC₅₀ = 0.1 nM) and cellular potency (SJSA-1 EdU IC₅₀ = 16 nM), as well as favorable pharmacokinetic properties. Compound 4 also shows excellent antitumor activity in the SJSA-1 osteosarcoma xenograft model with an ED₅₀ of 11 mg/kg. Optimization efforts toward the discovery of these inhibitors as well as the new interactions observed with the MDM2 protein are described herein.